Sep 2026· Frontiers in Cell and Developmental Biology· Vol 14· 0 citations· 112 references
Medicine
TL;DR
An emerging Frontier in ZAK pharmacology is discussed: the conceptual development of structure-guided, isoform-selective allosteric interventions designed to safely decouple pathogenic ZAKα signaling from essential ZAKβ-mediated tissue homeostasis.
Abstract
Mitogen-activated protein kinase kinase 20 (MAP3K20/ZAK) has emerged as a critical biophysical sensor, uniquely poised at the intersection of environmental stress and cellular fate. Its versatile signaling is primarily orchestrated by two structurally distinct splice variants: ZAKα, which drives the ribotoxic stress response (RSR) upon detecting ribosome collisions, and ZAKβ, which mediates homeostatic mechanotransduction. However, emerging evidence indicates that the biological roles of ZAK cannot be strictly categorized as either pathogenic or protective. It exhibits profound functional plasticity and engages non-canonical metabolic networks in a highly context-dependent manner. Consequently, dysregulated ZAK signaling acts as a powerful disease amplifier across diverse human pathologies, including aggressive malignancies, cardiac remodeling, systemic metabolic deterioration, and inherited myopathies. While targeting ZAK presents a compelling therapeutic opportunity, current broad-spectrum kinase inhibitors are heavily confounded by “on-target, off-tissue” toxicities, particularly within the epidermal barrier. In this review, we synthesize the structural mechanisms, downstream cascades, and complex pathobiology of ZAK. Furthermore, we discuss an emerging Frontier in ZAK pharmacology: the conceptual development of structure-guided, isoform-selective allosteric interventions designed to safely decouple pathogenic ZAKα signaling from essential ZAKβ-mediated tissue homeostasis.
This review systematically integrates advances in STAMBPL1 biology from structural to translational studies, highlighting its promise as a therapeutic target for precision cancer therapy.
Hu Lei, Han-Zhang Xu, Li Yang et al.· Molecular Biology Reports· 0 citations
It is proposed that UBA1 functions as a proteostasis-innate immunity checkpoint whose biological output is determined by residual enzymatic activity, subcellular distribution, lineage context, and clone size and suggests a mechanism-based approach to therapeutic intervention in VEXAS syndrome and malignancy.
Yan-Yu Zhang, Quan-Xin Su· Frontiers in Immunology· 0 citations
Receptor-interacting protein kinase 1 (RIPK1) plays a pivotal role in regulating cell survival and death, thereby exerting complex and multifaceted functions in the initiation and progression of cancer. Its expression is frequently dysregulated across diverse malignancies and correlates strongly with poor prognosis, hi...
Jing-Yu Luo, Shu-Ya Song, Ze-Kun Li et al.· Cellular Signalling· 0 citations
The development of KRAS inhibitors is explored, highlighting the challenges due to KRAS’s ‘undruggable’ nature and the success of covalent inhibitors such as sotorasib for KRASG12C mutant cancers, and the ubiquitin–proteasome system is highlighted as key regulators of KRAS stability and signaling networks, providing co...
Yeonjoo Lee, Sua Hwang, Hyungkyung Shin et al.· Experimental and Molecular M...· 0 citations
INTRODUCTION
Ribotoxic stress is an evolutionarily conserved intracellular surveillance mechanism that detects disturbances in translational fidelity and links ribosomal damage to inflammatory and stress-responsive signaling pathways. Diverse pathological stimuli, including microbial toxins, oxidative stress, metabolic...
Kamlesh Sahu, Trilochan Satapathy· Recent advances in inflammat...· 0 citations
Cancer progression is shaped not only by genetic alterations but also by dynamic remodeling of regulated cell death. MicroRNAs (miRNAs) have emerged as central regulators of these processes by coordinating gene expression, metabolic balance, and stress responses. This review summarizes current understanding of how miRN...
Di Xiao, Yan-Zhou Luo, Li-Yuan Liu et al.· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.